Anaemia in Chronic Heart Failure
|
|
- Darcy Hawkins
- 5 years ago
- Views:
Transcription
1 Anaemia in Chronic Heart Failure 2011 Update Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland
2 DECLARATION OF CONFLICT OF INTEREST Consultancy fees and speaker s honoraria from: Vifor Pharma Ltd, Amgen
3 Heart Failure Patient Importance of co-morbidities HF pathophysiological mechanisms CV & non-cv co-morbidities Clinical picture (symptoms) Disease progression Outcome Management
4 Anaemia in Heart Failure 1. Prevalence 2. Contributing factors and mechanisms 3. Consequences: a. pathophysiology b. symptoms & QoL c. outcome 4. Therapy
5 US National Health & Nutrition Examination Survey; Guralnik JM, et al Blood 2004; Prevalence of anaemia in HF How to define anaemia in HF? Distribution of haemoglobin in persons > 65 years N = 4199 Anaemia at age > 65y M 11%; F 10% (age > 85y 20%+) Mostly mild 1/3 unexplained WHO definition
6 Lopez-Sendon J; ESC 2005 Prevalence of anaemia in HF % Registries Clinical Trials
7 Ambulatory pts: Prevalence of anaemia in HF Tang WH et al., JACC 2008;51: Cleveland Clinic; internal med and cardiology outpatient departments; year Anaemia: Hb<11g/dL (women) & < 12 g/dl (men) Prevalence (overall): 17% Dunlay SM et al., Am J Med 2008;121: Community study; Olmsted County; retrospective: & prospective: Anaemia: Hb<12 g/dl (women) & < 13 g/dl (men) Prevalence (overall): retrospective 40%, prospective 53% (HFPEF 58%) Hospitalized pts: Young JB et al., Am J Cardiol 2008;101: Patients hospitalized with HF, OPTIMIZE-HF; Prevalence: 50% had Hb<12.1 g/dl, 25% had Hb g/dl (Hb quartiles)
8 Prevalence of anaemia in HF How to define anaemia in HF? UK General Practice Research Database; N=20131 pts with stable angina & N=14741 pts with first MI; follow-up -3.2yrs Adjusted HR for mortality 11.9 g/dl 13.1 g/dl Shah AD et al., PLoS 2011;8:e
9 Prevalence of anaemia in HF How to define anaemia in HF? Relationship Between Baseline Hemoglobin and Annual Mortality in HF Metaanalysis; 34 studies, HF patients; 37% anaemic Groenveld HF et al. JACC 2008;52:
10 Anaemia in Heart Failure 1. Prevalence 2. Contributing factors and mechanisms 3. Consequences: a. pathophysiology b. symptoms & QoL c. outcome 4. Therapy
11 Clinical characteristics associated with increased risk of anaemia in HF Advanced age Female gender Chronic renal disease Severity of heart failure Acute settings (hemodilutions) Other co-morbidities (DM) Decreased BMI Use of ACE-I / ARBs / (BB?) Tang and Katz, Circulation 2006
12 Potential mechanisms underlying anaemia in HF LV dysfunction Kidney RAS&SNS activation EPO secretion Plasma volume expansion Haemodilution EPO resistance Bone Marrow Dysfunction RBC production Anemia Modified from Felker GM,JACC 2004;44:959; Tang Y, Circulation 2006;113:2454
13 Potential mechanisms underlying anaemia in HF LV dysfunction Kidney RAS&SNS activation EPO secretion Iron deficiency (absolute & functional) Plasma volume expansion Haemodilution Bone Marrow Dysfunction EPO resistance RBC production Anemia Modified from Felker GM,JACC 2004;44:959; Tang Y, Circulation 2006;113:2454
14 Anaemia of chronic disease the most frequent cause of anaemia in HF Other 57% 14% Anaemia of chronic disease N=148 anaemics 5% Opasich C et al.; Eur Heart J 2005 Iron deficiency 24% Renal disease Iron deficiency for erythropoiesis 64% Defective endogenous EPO production 76%
15 Controversies around endogenous EPO in HF Elevated levels of circulating EPO in HF Volpe M et al., AJC 1994 van der Meer P et al., JACC 2004 Elevated EPO levels poor prognosticator George J et al., Arch Intern Med Belonje AMS, Circulation 2010 In anaemic HF pts impaired EPO responsiveness (level lower than expected) Belonje AMS, Circulation 2010 lower than expected EPO levels EPO levels as expected Belonje AMS et al. Circulation 2010;121: Higher than expected EPO levels (worse prognosticator)
16 Jankowska EA et al. Eur Heart J 2010 Iron deficiency in patients with HF Prospective observational study, 546 patients with stable systolic HF ID: ferritin <100 μg/dl, or μg/dl with TSAT<20% % of HF pts 50% p< ±10 p= ±12 40% 37±4 p= ±6 p=0.03 p= ±6 41±6 30% 20% 37±4 32±4 34±4 31±5 32±6 32±6 10% 0% All patients
17 Definition of Iron Deficiency in HF Functional vs Absolute Anaemia (Hb <12 g/dl) ID-Anaemia Iron Deficiency (no Anaemia) 1. absolute ID (depletion of iron stores) causes: chronic blood loss (ASA, anticoagulants), inadequate intake (elderly, malnutrition, impaired absorption) diagnosis: low ferritin level (<30? <100?) 2. functional ID (impaired iron utilization; iron stores ~) causes: chronic inflammation & renal dysfunction diagnosis: ferritin ~ N (< 300) & TSAT<20%
18 Myocardial iron is depleted in HF Myocardial Iron Content Regulation of TfR Expression Myocardial TfR Expression Patients with advanced HF demonstrated evidence of iron deficiency in the blood and in the myocardium (generalised disorder?) Potential role of neurohormonal activation in disturbed iron metabolism Maeder MT et al. JACC 2011;58:474-80
19 Anaemia in Heart Failure 1. Prevalence 2. Contributing factors and mechanisms 3. Consequences: a. pathophysiology b. symptoms & QoL c. outcome 4. Therapy
20 Anaemia: cause or (and) consequence of HF Chicken or egg: Which comes first?
21 Anaemia: cause and consequence of HF HF worsening Remodelling LVH cell death LV diameter Plasma volume Oedema Anaemia HF Tissue Hypoxia Peripheral vasodilatation Blood pressure Activation of SNS Increased Salt & Water Retention Renal blood flow RAA, ADH
22 What affects exercise tolerance: anaemia or iron deficiency? Iron deficiency (ID) F=12.72 p<0.001 Anemia F=2.13 p=0.15 Interactions F=0.01 p=0.94 Peak VO 2 (ml/min/kg) ID (-) Anemia (-) ID (-) Anemia (+) ID (+) Anemia (-) ID (+) Anemia (+) Jankowska EA et al., JCF 2011 (in press)
23 Anaemia in HF adversely affects the outcome Meta-analysis, 34 studies, N= HF patients; anaemics 37% Mortality: anaemics 46.8% vs non-anaemics 29.5%; OR=1.96 ( ) Anaemia independent risk of mortality; adjusted HR 1.46 ( ) Groenveld HF et al., JACC 2008;52:818 CHARM program Per 1000 pt-years Death Anaemics Non-anaemics Per 1000 pt-years Hospital admission CV Non-CV Reduced LVEF CV Non-CV Preserved LVEF CV Non-CV Reduced LVEF CV Non-CV Preserved LVEF O Meara E et al., Circulation 2006;113:986
24 Laboratory Values and Outcome CHARM CV Death/HF Hospitalisation Model 952 events Variable 2 HR* Age (per 10 yrs over age 60) NYHA Class III/IV /2.09 Cardiomegaly Diabetes (insulin/other) /1.07 RDW (%) Prior HF Hosp Bilirubin (total) Ejection fraction (per 5% <45%) * per SD for continuous variables % lymphocytes, uric acid, glycosylated Hgb, Hgb, creatinine were also all independent predictors
25 Jankowska EA et al. Eur Heart J 2010 Iron deficiency: an ominous sign in patients with systolic HF Prospective observational study, 546 patients with stable systolic CHF ID: ferritin <100 μg/dl, or μg/dl with TSAT<20% Cumulative event-free survival Patients without ID: Survival: 67% 95% CI: 61-72% p= Patients with ID: Survival: 53% 95% CI: 46-61% ID (but not anaemia) related to an increased risk of death or HTX: HR (adjusted) = 1.6 (95% CI , p<0.01) Follow-up (months)
26 Anaemia in Heart Failure 1. Prevalence 2. Contributing factors and mechanisms 3. Consequences: a. pathophysiology b. symptoms & QoL c. outcome 4. Therapy
27 Anaemia in heart failure: how (and whether) to treat? Rationale (already very strong) Treatment options: Blood transfusions Demetri GD et al. Br J Cancer 2001 Erythropoietin or ESPs (in combination with iron and vit B 12 /folate) Silverberg D et al. J Am Coll Cardiol 2000 & 2001 Mancini DM et al. Circulation 2003; Palazzuoli et al. AHJ 2006 & 2007 AMGEN programme Iron (oral or iv) Bolger AP et al., JACC 2006; Toblii JE et al. JACC 2007; Okonko DO, JACC 2008; FAIR-HF Anker SD et al., NEJM 2009
28 Anaemia therapeutic target in CHF? Pooled risk ratio for mortality in randomized, placebo-controlled trials of erythropoiesis-stimulating agent treatment in patients with heart failure and anaemia. Desai A et al. Eur J Heart Fail 2010;12:
29 Poor initial hematopoietic response to ESA may be associated with poor outcome Solomon SD et al., NEJM 2010;363:1146 Death, Myocardial Infarction, Stroke, Heart Failure, or Hospitalization for Myocardial Ischemia poor initial response DA the lowest quartile of % change in Hb level (<2%) after the first 2 standardized doses of the drug
30 Results Patient Global Assessment NYHA functional class 6-minute walk test KCCQ overall score EQ-5D VAS score EQ-5D, European Quality of Life 5-Dimensions; KCCQ; Kansas City Cardiomyopathy Questionnaire; VAS; visual analog scale. Anker SD et al. New Engl J Med 2009;361:
31 Anaemia in Heart Failure Conclusions 1. Prevalence common, affecting 20-40% pts several contributing factors (age, severity, renal dysfunction, co-morbidities) 2. Complex pathophysiology hemodilution, impaired EPO production/signalling, iron deficiency, ACD 3. Clinical consequences: associated with exercise intolerance, poor quality of life, high M&M 4. Therapy not yet established whether it can become therapeutic target
32 100% Lab test performed by cardiologist to diagnose/confirm and explore cause of anaemia in HF patients 90% 80% 70% 80% 77% 85% 71% 86% 84% 68% 63% 60% 50% 51% 51% 47% 40% 35% 30% 20% 10% 8% 8% 6% 8% 5% 18% 11% 13% 10% 9% 10% 4% 0% Hb Ferritin TSAT None Total (1155) France (268) Germany (258) Spain (254) Switzerland (125) UK (250) Hb assessment undertaken ~ 80% of patient, ferritin measured in ~ 40% In 10% of HF patients none of these tests (Hb, ferritin or TSAT) is performed Mori C et al., ESC 2011 presentation
33
34 I.V. Iron Performs Better than Placebo in all Patient Subgroups Anker SD et al. N Engl J Med 2009;36: Self-reported PGA score NYHA functional class
35 Impact of i.v. FCM on renal function P=0.054 P=0.049 P=0.017 Treatment effect (ml/min/1.73m 2 ):* 2.8 ± ± ± 1.7 * LSM mean ± SE
36 Importance of iron Essential for growth and survival CELLS TISSUES ORGANS BODY POPULATION Iron is particularly important for cells of high mitogenic potential and high energy demand, e.g. skeletal myocytes and cardiomyocytes.
37 HAEMATOPOIETIC TISSUES ERYTROPOIESIS (IMMUNE CELLS, PLATELETS) Anaemia Oxygen carrying capacity ( Hb) Symptoms O 2 -transportation-dependent (Maximal performance) Importance of iron Adapted from Haas JD & Brownlie T. J Nutr 2001;131:676S 690S IRON DEFICIENCY (ID) EXTRA-HAEMATOPOIETIC TISSUES SKELETAL MUSCLES (MYOCARDIUM, ADIPOSE TISSUE, LIVER, KIDNEYS, BRAIN) Oxygen storage (myoglobin) Tissue oxidative capacity Energetic efficiency Anaerobic metabolism ID = Mitochondrial Dysfunction Symptoms Tissue ID-dependent (Endurance) EXERCISE INTOLERANCE
Iron deficiency in heart failure
Iron deficiency in heart failure Piotr Ponikowski, MD, PhD, FESC Department of Heart Diseases, Wroclaw Medical University Centre for Heart Diseases, Military Hospital, Wroclaw, Poland Objectives Importance
More informationIron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD
Iron Deficiency: New Therapeutic Target in Heart Failure Stefan D. Anker, MD PhD Department of Cardiology, Applied Cachexia Research, Charité Campus Virchow-Klinikum, Universitätsmedizin Berlin, Germany.
More informationAnemia and Iron Deficiency: What Every Cardiologist Needs to Know
6th Saudi HF Group Symposium Riyadh - December 8-9, 2017 Anemia and Iron Deficiency: What Every Cardiologist Needs to Know Ammar Chaudhary MBChB, FRCPC Consultant Cardiologist Advanced Heart Failure Department
More informationΔιαχείριση ασθενούς με καρδιακή ανεπάρκεια και αναιμία. Βασιλική Μπιστόλα Καρδιολόγος Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο Αττικό
Διαχείριση ασθενούς με καρδιακή ανεπάρκεια και αναιμία Βασιλική Μπιστόλα Καρδιολόγος Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο Αττικό Based on WHO Definition, 9% of Adults Have Anemia: ARIC Study*
More informationComorbidities in Heart Failure: Iron Deficiency. Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah
Comorbidities in Heart Failure: Iron Deficiency Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah ACC Middle East Conference 2018 Iron Deficiency in Heart Failure
More informationEffect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)
Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet Georg Ertl, Michel Komajda,
More informationErythropoiesis Stimulation and Heart Failure: Current Status
Erythropoiesis Stimulation and Heart Failure: Current Status Marc A. Pfeffer, MD, PhD Dzau Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham & Women s Hospital Boston, Massachusetts
More informationIron-Deficiency Anemia and Heart Failure
Iron-Deficiency Anemia and Heart Failure SUNNY LINNEBUR, PHARMD, BCPS, BCGP PROFESSOR, UNIVERSITY OF COLORADO Objectives 1. Describe the impact of iron deficiency anemia on the heart failure patient 2.
More informationRED CELL DISTRIBUTION WIDTH
RED CELL DISTRIBUTION WIDTH A NEW MARKER OF EXERCISE INTOLERANCE IN PATIENTS WITH CHRONIC HEART FAILURE Emeline Van Craenenbroeck, Paul Beckers, Nadine Possemiers, Christiaan Vrints, Viviane Conraads Cardiology
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationIron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016
Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationHF-PEF: Symptoms, quality of life and mortality/morbidity
HF-PEF: Symptoms, quality of life and mortality/morbidity May 21, 2011 John McMurray, MD Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham & Women s Hospital Boston; Visiting Professor of Medicine,
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationSupplementary Online Content
Supplementary Online Content Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency:
More informationHeart Failure with Preserved Left Ventricular Ejection Fraction. (HFpEF)
Thessaloniki, May 27, 2017 Heart Failure with Preserved Left Ventricular Ejection Fraction Filippos Triposkiadis, MD, FESC, FACC Professor of Cardiology Director, Department of Cardiology Larissa University
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationPresent and future options in the pharmacological treatment of heart failure
Present and future options in the pharmacological treatment of heart failure Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg Gö teborg, Sweden Symptomatic heart failure
More informationUniversity of Groningen
University of Groningen Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients Ngo, Katherine; Kotecha, Dipak; Walters, Julia A. E.; Manzano, Luis; Palazzuoli, Alberto; van Veldhuisen,
More informationHeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationHeart Failure A Disease for the Internist?
Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices
More informationIron, combination therapies and new drugs on horizon
Anaemia and iron deficiency in HF Iron, combination therapies and new drugs on horizon Piotr Ponikowski, MD, PhD, FESC Wroclaw Medical University Military Hospital Wroclaw, Poland Disclosure Consultancy
More information2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland
2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland Disclosures Consultancy fees and speaker s honoraria from: Amgen, Servier, Novartis, Johnson & Johnson, Merck, Berlin Chemie,
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationHFpEF 2016 : Comorbidities and Outcomes
HFpEF 2016 : Comorbidities and Outcomes Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine, Duke University Editor in Chief, JACC: Heart
More informationPeri-Surgical Anemia and the TAVR Patient
Peri-Surgical Anemia and the TAVR Patient Kathrine P Frey, MD Fairview Southdale Hospital Director of Blood and Pre-Operative Anemia Management April, 2015 MIDWEST VALVE SYMPOSIUM, April 2015 Credentials
More informationTreatment of sleep apnea in heart failure patients after SERVE-HF results
Treatment of sleep apnea in heart failure patients after SERVE-HF results Martin R Cowie Professor of Cardiology National Heart & Lung Institute Imperial College London (Royal Brompton Hospital Campus)
More information12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker
12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,
More informationUniversity of Groningen. Iron status and heart failure Klip, IJsbrand Thomas
University of Groningen Iron status and heart failure Klip, IJsbrand Thomas IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationUNDERSTANDING BLOOD TESTS
UNDERSTANDING BLOOD TESTS Parminder Chaggar Cardiology SpR Northern General Hospital Sheffield Conflict of Interest: Nil OVERVIEW Monitoring drug titration Markers of risk Iron deficiency Thyroid disease
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationShould I use statins?
I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationFREQUENCY OF ANEMIA AND CLINICAL OUTCOME IN PATIENTS WITH CONGESTIVE HEART FAILURE. Malik Faisal Iftekhar, Abdul Sami,Imran Khan, Akhter Sher
Pak Heart J ORIGINAL ARTICLE FREQUENCY OF ANEMIA AND CLINICAL OUTCOME IN PATIENTS WITH CONGESTIVE HEART FAILURE 1 2 3 4 Malik Faisal Iftekhar, Abdul Sami,Imran Khan, Akhter Sher 1-4 Hayatabad Medical Complex,
More informationStefan D. Anker, MD PhD
Drug therapy in HF &m anaging co-morbidities in HF: focus on iron deficiency -- Delhi, 07. February 2015 -- Stefan D. Anker, MD PhD Dept. für Innovative Clinical Trials Universitätsmedizin Göttingen (UMG)
More informationHeart Failure in Women
Heart Failure in Women Disclosure Professor Sindone has received honoraria, speaker fees, consultancy fees, is a member of advisory boards or has appeared on expert panels for: Professor Andrew Sindone
More informationNew horizons in HF: potential of new drugs
New horizons in HF: potential of new drugs Marc A. Pfeffer, MD, PhD Dzau Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham & Women s Hospital Boston, Massachusetts FINANCIAL
More informationGerasimos Filippatos MD, FESC, FCCP, FACC
Gerasimos Filippatos MD, FESC, FCCP, FACC Head of HF Unit at Athens University Hospital, Greece President (2014-2016) of the HF Association of the European Society of Cardiology (ESC) Served as Chair of
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationIron Therapy. Dr Kiran Desai Consultant In Gastroenterology Walsall Manor Hospital
Iron Therapy Dr Kiran Desai Consultant In Gastroenterology Walsall Manor Hospital CONFLICTS OF INTEREST Vifor Pharma /Abbvie consultant on their advisory board. Aims 1. Why is it important to understand
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationBiological Correlates of Frailty in Older Heart Failure Patients
Biological Correlates of Frailty in Older Heart Failure Patients Dalane W. Kitzman, MD Professor of Internal Medicine: Cardiovascular Medicine and Geriatrics Kermit Glenn Phillips II Chair in Cardiology
More informationIRON DEFICIENCY / ANAEMIA ANTHONY BEETON
IRON DEFICIENCY / ANAEMIA ANTHONY BEETON HYPOXIA 1-2 mg IRON Labile iron Body iron ± 3 4 g Liver and the reticuloendothelial system and spleen (approximately 200 300 mg in adult women and 1 g in adult
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationDiastolic Heart Failure Uri Elkayam, MD
Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A
More informationHeart Failure. GP Update Refresher 18 th January 2018
GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationTake-home Messages from Recent Heart Failure Trials: Heart Rate as a Target
Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationWhat is established? Risk of Benefit complica comp tion
What s new in exercise training in CHF? Jean-Paul Schmid, MD, FESC Consultant Cardiologist, SpitalNetzBern Tiefenau Hospital, Dept. of Internal Medicine, Cardiology, Bern, Switzerland What is established?
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationDiastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure
Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationEfficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis
Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Dipak Kotecha, MD PhD on behalf of the Selection of slides presented at the European
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationThe Role of Cardiac Rehabilitation. The Role of Cardiac Rehabilitation. in Heart Failure. in Heart Failure. History of Cardiac Rehab.
The Role of Cardiac Rehabilitation The Role of Cardiac Rehabilitation in Heart Failure in Heart Failure Kate Traynor RN MS FAACVPR Financial Disclosures No relevant financial relationship exists. History
More informationClinical Phenotypes and In-hospital Management and Prognosis in Diabetic versus Non-diabetic Patients with Acute Heart Failure in ALARM-HF Registry
Clinical Phenotypes and In-hospital Management and Prognosis in Diabetic versus Non-diabetic Patients with Acute Heart Failure in ALARM-HF Registry J T. Parissis, A. Mebazaa, V. Bistola, I. Ikonomidis,
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationThe FIND-CKD Study Background Study design (Results)
The FIND-CKD Study Background Study design (Results) The FIND-CKD Study An open-label, multicentre, randomized, 3 arm study comparing the 12-month efficacy and safety of Ferric carboxymaltose (FCM, Ferinject
More informationIdentification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationManagement of Stage B Heart Failure
KSC 2017 Management of Stage B Heart Failure Byung Su Yoo, MD., PhD. Division of Cardiology, Wonju College of Medicine, Yonsei University, South Korea Focused on Symptom ASLVSD, ASLVDD LVH HF progression
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationThe role of angiotensin II receptor blockers in the management of heart failure
European Heart Journal Supplements (2005) 7 (Supplement J), J10 J14 doi:10.1093/eurheartj/sui057 The role of angiotensin II receptor blockers in the management of heart failure John J.V. McMurray* Department
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationHF-Preserved Ejection Fraction
HF-Preserved Ejection Fraction Justin A. Ezekowitz, MBBCh MSc FRCPC FACC FESC FAHA Associate Professor, University of Alberta Co-Director, Canadian VIGOUR Centre Cardiologist, Mazankowski Alberta Heart
More informationThe Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)
The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished
More informationWHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine
WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data Safety Monitoring Board SOPRANO (J&J), EVALUATE-HF
More informationManagement of Heart Failure from diagnosis to the grave. Richard Lawrance Consultant Cardiologist - WMH
Management of Heart Failure from diagnosis to the grave Richard Lawrance Consultant Cardiologist - WMH Case Presentation 55y man Breathless Ex tolerance 100yds on flat, limited by SOB No chest pain Borderline
More informationTreatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationCardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction
Journal of Geriatric Cardiology (2014) 11: 100 105 2014 JGC All rights reserved; www.jgc301.com Research Article Open Access Cardiovascular effects of hemoglobin response in patients receiving epoetin
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST TAKE HOME MESSAGES FROM RECENT HEART FAILURE CLINICAL TRIALS How to use aldosterone blockers? Faiez Zannad INSERM, U961 and Clinical Investigation Center CHU, Heart
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationIs Heart Rate a Treatment Target?
Is Heart Rate a Treatment Target? M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin) Universitätsklinikum des Saarlandes Homburg/Saar michael.boehm@uks.eu Heart Rate
More informationTo Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure
To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure Pramila S Kudtarkar*, Mariya P Jiandani*, Ashish Nabar** Abstract Purpose
More information